David Chen Lab

Epigenetic dysregulation plays an important role in cancer initiation, progression and therapeutic responses. Dr. Chen’s research goal is to provide novel and more effective cancer therapies by understanding how epigenetic regulators control oncogene expression under normal and malignant conditions. His recent study based on a genome-wide functional genetic screen identified epigenetic circuitries that drive the mixed lineage leukemias (Chen et al. 2015, Nature Medicine), and led the current research towards combinational epigenetic therapies in multiple types of hematopoietic malignancies.
Dr. Chen and his laboratory in the Department of Systems Biology will focus on dissecting the epigenetic mechanisms underlying the therapeutic resistance in cancers. He is skilled in high throughput CRISPR genetic screens for de novo therapeutic target discovery. He also utilizes next-generation sequencing for epigenomic and transcriptomic analyses (ChIPseq, ATACseq, RNAseq, etc.). In addition, Dr. Chen’s laboratory is involved in leading-edge technology development, including precision epigenome editing and transcriptional regulations.